StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note released on Saturday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The firm has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. The stock’s 50 day simple moving average is $0.14. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a one year low of $1.22 and a one year high of $8.45.
Nabriva Therapeutics Company Profile
Read More
- Five stocks we like better than Nabriva Therapeutics
- What to Know About Investing in Penny Stocks
- 3 Insider-Buy Stocks to Add to Your Watchlist Now
- What Investors Need to Know About Upcoming IPOs
- Commvault Stock: AI Cybersecurity Giant Ready to Double Again
- Stock Analyst Ratings and Canadian Analyst Ratings
- Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.